Michael Goldberg - Echo Therapeutics Director
Director
Dr. Michael M. Goldberg M.D. is Independent Director of the Echo Therapeutics Inc.. Dr. Goldberg was appointed by our Board of Directors in February 2014 to fill a vacancy and was elected a director by our stockholders on June 19 2014. He was elected the Chairman of the Board on January 5 2015. He was a Managing Member of Montaur Capital LLC since January 2014 and was a Managing Partner of Montaur Capital Partners from February 2007 to December 2013. Prior to that Dr. Goldberg was with Emisphere Technologies Inc. serving as Chief Executive Officer from August 1990 to January 2007 Chairman of the Board of Directors from November 1991 to January 2007 and President from August 1990 to October 1995. Before joining Emisphere Dr. Goldberg served as Vice President of The First Boston Corporationration where he was a founding member of the Healthcare Banking Group. Dr. Goldberg currently serves on the board of Navidea Biopharmaceuticals. He was a Director of Alliqua Inc. Urigen Pharmaceuticals Inc. Adventrx Pharmaceuticals Inc. and several private companies since 2014.
| Age | 56 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 732-201-4189 |
| Web | http://www.echotx.com |
Michael Goldberg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Goldberg against Echo Therapeutics stock is an integral part of due diligence when investing in Echo Therapeutics. Michael Goldberg insider activity provides valuable insight into whether Echo Therapeutics is net buyers or sellers over its current business cycle. Note, Echo Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Echo Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Goldberg over two weeks ago Acquisition by Michael Goldberg of 3686 shares of Caredx subject to Rule 16b-3 |
Echo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (359.77) % which means that it has lost $359.77 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.649) %, meaning that it created substantial loss on money invested by shareholders. Echo Therapeutics' management efficiency ratios could be used to measure how well Echo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 3.52 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Echo Therapeutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Echo Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Echo Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Echo Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Echo to invest in growth at high rates of return. When we think about Echo Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Judy Olian | Mattel Inc | 66 | |
| Anne Cooney | Summit Materials | 61 | |
| Dirk Put | Mattel Inc | 55 | |
| Anne Wade | Summit Materials | 48 | |
| Barbara Samardzich | BRP Inc | 60 | |
| Ted Gardner | Summit Materials | 61 | |
| Estelle Metayer | BRP Inc | 47 | |
| Kathy Loyd | Mattel Inc | 66 | |
| Joseph Robbins | BRP Inc | 37 | |
| Daniel Avramovich | US Silica Holdings | 62 | |
| Edward Philip | BRP Inc | 53 | |
| Michael Stice | US Silica Holdings | 58 | |
| Joshua Bekenstein | BRP Inc | 59 | |
| J Bombardier | BRP Inc | 74 | |
| Daniel ONeill | BRP Inc | 65 | |
| William Cary | BRP Inc | 58 | |
| Nicholas Nomicos | BRP Inc | 54 | |
| Louis Laporte | BRP Inc | 56 | |
| Frances Fergusson | Mattel Inc | 72 | |
| Soren Laursen | Mattel Inc | 54 | |
| Julia Kahr | Summit Materials | 37 | |
Management Performance
| Return On Equity | -3.65 | |||
| Return On Asset | -359.77 |
Echo Therapeutics Leadership Team
Elected by the shareholders, the Echo Therapeutics' board of directors comprises two types of representatives: Echo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Echo. The board's role is to monitor Echo Therapeutics' management team and ensure that shareholders' interests are well served. Echo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Echo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Goldberg, Director | ||
| Scott Hollander, CEO and President and Director | ||
| Elazer Edelman, Director | ||
| Christine Olimpio, Director of Investor Relations and Corporate Communications | ||
| Alan Schoenbart, CFO | ||
| Shepard Goldberg, Director |
Echo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Echo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.65 | |||
| Return On Asset | -359.77 | |||
| Current Valuation | 3.43 M | |||
| Shares Outstanding | 12 M | |||
| Number Of Shares Shorted | 273.27 K | |||
| Price To Earning | (0.03) X | |||
| Price To Book | 3.11 X | |||
| Price To Sales | 990.09 X | |||
| Revenue | 5.12 K | |||
| Gross Profit | 5.12 K |
Pair Trading with Echo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Echo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Echo Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Visa could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Visa when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Visa - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Visa Class A to buy it.
The correlation of Visa is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Visa moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Visa Class A moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Visa can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Echo Stock
If you are still planning to invest in Echo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Echo Therapeutics' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |